---
title: "RAILY AESMED issues a profit warning, expecting a loss attributable to shareholders of approximately HKD 59 million in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231239502.md"
description: "RAILY AESMED issued a profit warning, expecting a loss attributable to owners of approximately 59 million yuan in 2024, compared to a loss of 32 million yuan in 2023. Revenue is expected to be around 199 million yuan in 2024, an increase from 189 million yuan in 2023. The loss is mainly due to an impairment provision for goodwill and intangible assets of about 55 million yuan, as well as an increase in stock option expenses to 8 million yuan. The company is increasing its R&D investment in Suzhou Ruichuan Biomedical Technology Co., Ltd., with expected management and R&D expenses of 5 million yuan"
datetime: "2025-03-10T14:44:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231239502.md)
  - [en](https://longbridge.com/en/news/231239502.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231239502.md)
generator: "portal-rs"
---

# RAILY AESMED issues a profit warning, expecting a loss attributable to shareholders of approximately HKD 59 million in 2024

According to the Zhitong Finance APP, RAILY AESMED (02135) announced that it expects the group to achieve revenue of approximately RMB 199 million in 2024, compared to approximately RMB 189 million in 2023; the loss attributable to the owners of the company is expected to be approximately RMB 59 million, while the loss attributable to the parent company owners in 2023 was approximately RMB 32 million.

The announcement stated that the board of directors believes that the continued losses are mainly due to the following reasons: a cumulative goodwill impairment provision and an intangible asset impairment provision of approximately RMB 55 million for the entire year (offset by related deferred tax items), and a reversal of contingent consideration of approximately RMB 18 million; in the fiscal year 2024, the group's stock option expenses are expected to increase to approximately RMB 8 million (2023: approximately RMB 4 million).

In addition, to accelerate the research and development and production of the group's medical device products, the group has increased its investment in the research and development activities of its indirectly non-wholly-owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd. (formerly known as "Suzhou Yonglan Biomedical Technology Co., Ltd.") (Suzhou Ruichuan). In the fiscal year 2024, the management and research and development expenses of Suzhou Ruichuan are expected to be approximately RMB 5 million, and these expenses have not yet been recovered from the economic benefits generated in 2024

### Related Stocks

- [02930.HK](https://longbridge.com/en/quote/02930.HK.md)
- [02935.HK](https://longbridge.com/en/quote/02935.HK.md)
- [02135.HK](https://longbridge.com/en/quote/02135.HK.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [Raily Aesthetic Medicine expects H1 profit attributable to shareholders of about RMB 4 million, swings from loss](https://longbridge.com/en/news/295241551.md)
- [Raily Aesthetic Medicine FY26 interim profit turns to RMB 3.51 million; revenue rises 35.7% to RMB 114.78 million](https://longbridge.com/en/news/297329762.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**